When life gives you sour mandarins...

Thanks so much to @anzuptrials.bsky.social for helping us starting putting the NZ into ANZUP - great ideas shared on the day for clinical trials for people with GU and prostate cancers in NZ and maybe also AUS as well!

Fantastic to have this critical advice for older people with cancer - thank you @crisbergerot.bsky.social @bogda-koczwara.bsky.social and team

Online today! *Aging, Immune Fitness and Cancer* 🔬 Learn the latest about the intersection between these processes in @natrevcancer.nature.com 🧬 Great to work with @sandramcallister.bsky.social lab again 😁 doi.org/10.1038/s415...

One more of my votes for the #Hottest100 #TripleJ in the #Hottest200 today... The Whitlams - Blow Up The Pokies www.youtube.com/watch?v=7B49..., still as relevant today www.theguardian.com/australia-ne...

Question remains, is the abscopal effect real? Or is #RT just additive? Certainly evidence for modifying TME, intriguing data for WNT-mt patients when adding #radiotherapy to #PD1 #immunotherapy, but the idea of #RT being a 'vaccine', expanding the immune repertoire, is shown in just 1-2 patients.

The Renal IGW is fast approaching. Concept submissions close in 1 week! Register your attendance here anzup.org.au/idea-generat... @craiggedye.bsky.social

Two opinions that to my surprise are either unpopular or not widely held: 1. The control arm of a randomised trial should be best standard of care. 2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.

Great kickoff to clinical trials workshop #ANZUP25 — #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social

Tremendous insights with immediate patient impact; using genomic data we can collect routinely from today's patients, we may be able to predict upfront resistance, rather than subject people to 3-4 cycles of chemo, and we might also be strategic if we know people have sensitive cancers - bravo!

Friends, I have news. It is very good news. You'll just have to read it, I'm afraid. jamesclaims.substack.com/p/introducin...

Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies www.nature.com/articles/s41...

Meet Cherrie, one of the earliest participants in the CHALLENGE trial, and my colleague Janette Vardy talking about what these results mean. www.9news.com.au/videos/natio...

Presenting at #ASCO25 today! I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not. Cc @dusetzinas.bsky.social

#Teletrials in action: a generous and kind participant called me this week for Visit #3 of his participation in @anzuptrials.bsky.social #ANZadapt #clinicaltrial. “Where are you?”, I asked. “Let me send you a photo”, he said. How’s the serenity…

🚨 Public consultations now open: help shape how medicine information is shared with patients. We are reviewing the template used for EU package leaflets. Have your say on how to make them more understandable and relevant to patients. 🔗 Learn more & share your input: europa.eu/!TCm47q

Excellent, thought-provoking presentation by Deb Maskens of IKCC on the % of patients that are not being reached by #KidneyCancer organisations and strategies to consider on how we can improve. #IKCC25 @debmaskens.bsky.social

Welcome @myesmo.bsky.social!

Great piece from Lancet Global Health on democratising clinical trials research to strengthen primary healthcare, relevant to ALL healthcare. Every healthcare intervention is a clinical trial of n = 1; why not learn from every patient, every clinician?

Psych. Science just published a paper showing that the "warm glow" of donations can reduce depressive symptoms (d = [0.19, 0.46]). Most impressively, "micro" donations (one Chinese cent, or $0.0014) appear sufficient to trigger these large effects. Big if true? Let's dive in.

Note to anyone writing #clinicaltrial protocols: the word ‘subjects’ is pejorative and rude – people suffering illness may become patients of healthcare services, but transform themselves into participants when they volunteer to take part in clinical trials. Subjects are things we took at school.

There was messenger, transfer, ribosomal... then there was micro, then there was long non-coding, then circular, then MySpace, then Tumblr, Insta, Snapchat, TikTok... and then I gave up counting...

Send in the clones. Two papers in this week's @nature.com compare/contrast personalized neoantigen mRNA vaccines, with extraordinary success as adjuvant therapy in pancreatic cancer, but not helping when given late in lung cancer. Targeting ALL clones of each person's cancer is essential.

Take your chemo at night? Retrospective analysis of two large clinical trials suggests when you take temozolomide (am, pm, night) makes no difference in survival in #glioblastoma. Side effects might be better if taken at night. academic.oup.com/nop/advance-... @eortc.bsky.social

Progress for chromophobe RCC at ASCO GU. Excited to check out the FOUR abstracts for #chRCC tomorrow (H31, H18, E21, E36) #chromophobe #GU25 @msaouel.bsky.social

Integrating #ExerciseOncology into ICI tx Our study highlights feasibility & benefits of a remote & personalized program High adherence 81% & significant improvements in QOL, emotional sympts & side effects @crisbergerot.bsky.social @narjustflorezmd.bsky.social

Finally meeting @asharpmedonc.bsky.social in person #GU25

Friends, I have written you a book on forensic metascience. It is free. You can have it. Happy St. Valentine's Day. If you wish to give me a gift back, you can use it to cause trouble - the greatest gift of all. open.substack.com/pub/jamescla...

Beautiful presentation by Prof Louise Emmett of the @anzuptrials.bsky.social #ENZAp trial of enzalutamide +/- LuPSMA: ✅ Improved OS ✅ Improved quality of life Published today in Lancet Oncology www.thelancet.com/journals/lan...

Overall survival improved adding LuPSMA to enza in people with high risk prostate cancer, with almost 40% taking LuPSMA post study @anzuptrials.bsky.social @ascocancer.bsky.social #GU25

Excited for Prof Louise Emmett presenting #ENZAp today at #GU25 on behalf of @anzuptrials.bsky.social @ascocancer.bsky.social

Is there synergy, or just additive? Would be very grateful to see outcomes vs. subsequent therapy in the control arm, specifically those who did vs. did not take PARPi/platinum later…

Further data helping us personalise advanced prostate cancer treatment from a meta-analysis from @mrcnihrtmrp.bsky.social @ascocancer.bsky.social #GU25

Congratulations @jabyrnesci.bsky.social on winning the well-deserved David Vaux Research Integrity Fellowship Award. bit.ly/4aVDilW

Modern-Day Oracles or Bullshit Machines? Jevin West (@jevinwest.bsky.social) and I have spent the last eight months developing the course on large language models (LLMs) that we think every college freshman needs to take. thebullshitmachines.com

#ScienceSaturday 🧵 ➡️ Immunotherapies targeting neoantigens can be effective in mediating long-term durable responses in advanced cancer patients. However, identifying these neoantigens from metastatic tumors can be logistically challenging.

Resident medical officers play a vital role in the healthcare system, working at the frontline of acute inpatient hospital care alongside nursing and allied health staff. It's a stressful time and this kind of behaviour is completely unacceptable. www.theguardian.com/australia-ne...

My new book ‘The Cancer Roadmap’ was launched today It’s for anyone affected by cancer It tells you what is it, what causes it, how it’s treated, who to trust, how to understand risk + spot red flags on social media when it comes to alternative cures. Get yours here lnk.to/TheCancerRoa...

PubMed down. Clinicaltrials.gov down too.

Clinical (and research) governance is like oxygen; you take it for granted, until it runs out and then you are left gasping...

No sooner had our @anzuptrials.bsky.social #GDISCO (ANZUP 2403) study open at Fiona Stanley Hospital in Perth, the first participant has been recruited! Well done to all involved in this important #BladderCancer study #SMHS #CancerAustralia @profiand.bsky.social

Tremendously important work

"The Carter Center is credited with helping to cure river blindness, trachoma and Guinea worm disease, which went from millions of cases in Africa and Asia in 1986 to a handful today." Be the change you want to see in the world. Vale Jimmy Carter, RIP.

Another step towards a blood test for #kidneycancer? When cells die some of their DNA is released into the blood. If a person has a cancer, some of the DNA comes from the cancer. If you can detect the cancer DNA, it may help find, follow and understand a person's cancer, may help guide treatment.

What clinical features should you pick up as an oncologist in a patient receiving systemic therapy? #basics #oncology #oncsky Good to know for medical students and people interested in oncology!

It is with great sadness that we mourn our cherished friend and colleague Felix Feng, MD. Felix was a distinguished physician-scientist and beloved at @ucsfhealth.bsky.social. His vision, dedication, and commitment inspired colleagues, peers everywhere, and patients. cancer.ucsf.edu/in-memoriam-...

#SABCS24 #bcsm #OncSky #MedSky In patients with #breastcancer, cognitive behavioral therapy + AM bright light therapy was more effective for #insomnia than usual treatment + a relaxation audio. cc @oncoalert.bsky.social

It's all over... I have failed to avoid #whamageddon. Good luck to all remaining survivors.

Even low levels of arsenic in drinking water raise kidney cancer risk | ScienceDaily - goo.gl/alerts/R958Lj #GoogleAlerts